Literature DB >> 3242585

Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

J Kallio1, R Lindberg, R Huupponen, E Iisalo.   

Abstract

1. The debrisoquine hydroxylation phenotype was assessed in 211 healthy subjects of Finnish Caucasian origin. 2. A bimodal distribution was observed in the urinary debrisoquine/4-hydroxydebrisoquin ratio. Eleven subjects (about 5%) were poor metabolizers of debrisoquine, when a ratio of 12.6 was used as the cut-off point. 3. The mean metabolic ratio of 35 extensive metabolizers taking oral contraceptives was slightly lower than that of extensive metabolizers not taking contraceptives. This indicates that oral contraceptives may change the phenotyping near the metabolic ratio of 12.6. 4. The metabolic ratios were determined in eight subjects using both 4 h and 6 h urine collection times. The metabolic ratios corresponded well with each other indicating the usefulness of the shorter 4 h collection time.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Methods; Cultural Background; Demographic Factors; Developed Countries; Ethnic Groups; Europe; Examinations And Diagnoses; Family Planning; Finland; Laboratory Examinations And Diagnoses; Metabolic Effects; Northern Europe; Oral Contraceptives; Physiology; Population; Population Characteristics; Scandinavia; Whites

Mesh:

Substances:

Year:  1988        PMID: 3242585      PMCID: PMC1386597          DOI: 10.1111/j.1365-2125.1988.tb05321.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

2.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

3.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  The disposition of debrisoquine in hypertensive patients.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Metabolism of progesterone and estradiol by microsomes and purified cytochrome P-450 RLM3 and RLM5.

Authors:  K C Cheng; J B Schenkman
Journal:  Drug Metab Dispos       Date:  1984 Mar-Apr       Impact factor: 3.922

8.  2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.

Authors:  D J Back; J L Maggs; H S Purba; S Newby; B K Park
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

9.  Debrisoquine oxidation in an Australian population.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  8 in total

Review 1.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

2.  Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.

Authors:  L Salminen; R Lindberg; H R Toivari; R Huupponen; T Kaila; E Iisalo
Journal:  Int Ophthalmol       Date:  1989-01       Impact factor: 2.031

Review 3.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

6.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.

Authors:  J Kallio; R Huupponen; M Seppälä; E Säkö; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.